H1N1 (Swine Influenza) - Drug Pipeline Landscape, 2023

H1N1 (Swine Influenza) - Drug Pipeline Landscape, 2023

The H1N1 flu (swine flu) is primarily caused by the H1N1 strain of the flu (influenza) virus. It is a communicable viral illness causing upper and lower respiratory tract infections.

Swine flu H1N1 infects the cells that line nose, throat and lungs. The virus enters body when contaminated droplets are inhaled or transfer live virus from a contaminated surface to eyes, nose or mouth.

The most common symptoms of H1N1 infection include difficulty in breathing, chest pain, dizziness, nasal secretions, chills, fever, cough, sore throat, decreased appetite, and in some cases and lower respiratory tract disease.

Healthcare practitioners look for signs and symptoms of influenza, including H1N1 flu (swine flu) during the diagnosis. Laboratory tests like swab culture test, rapid flu test etc, can also be suggested for diagnosis.

There are several treatment options for swine influenza, most commonly antiviral drugs like oseltamivir zanamivir peramivir and baloxavir are used. Symptoms can be eased through lifestyle changes and home remedies like drinking plenty of water and using pain relievers.

Major pharmaceutical companies are involved in the development of potential drug candidates to improve the H1N1 (Swine Influenza) treatment such as Baloxavir marboxil, mRNA-1010, CD388 and others. Key players involved in the development of therapies to treat H1N1 (Swine Influenza) are Abzyme Therapeutics LLC, Blue Water Vaccines Inc, Cidara Therapeutics Inc, Genentech USA Inc, Moderna Inc and others. Two drugs are under late-stage Phase III clinical trials and eight drugs are in Phase II clinical trials and some other drugs are under Phase I, Preclinical and Discovery stages of development.

In December 2022, Cidara Therapeutics announced issuance of first U.S patent for CD388.

Report Highlights

Global Insight Service's, H1N1 (Swine Influenza) - Drug Pipeline Landscape, 2023 report provides an overview of the H1N1 (Swine Influenza) pipeline drugs. This report covers detailed insights on H1N1 (Swine Influenza) drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. H1N1 (Swine Influenza) pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clincial trials, and key upcoming milestones are included.

Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.